RE: Paul LOADMAN, Professor of Pharmacokinetics23 Mar 2024 12:30
Great sleuthing, does appear he's a very good asset to have with you at AACR. Let's hope Avacta have some side meetings lined up to discuss license options.
RE: Clarification of what "in parallel" meant in yesterday's RNS22 Mar 2024 16:56
As was mentioned yesterday it could be easier to recruit patients in the UK because of the NHS and because geographically the cancer centers being used cover the whole of England.
Of course there is risk but the main risk is not the platform working it's whether AS blows all the money raised on something other than getting it to market.